Fundraising Fox
Pete Olson
Chief Scientific Officer at Iambic
San Diego, California, United States
Find your path to Pete
Sign up to see every warm intro you have to Pete
- Paths you didn't know you had: your email and LinkedIn already hold routes to Pete. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
About
Pete Olson, PhD, is the Chief Scientific Officer at Iambic Therapeutics, a clinical-stage biotechnology company that applies AI models for protein structure prediction and drug design alongside high-throughput chemistry and biology experimentation. He previously served as VP, Research at Mirati Therapeutics, which was acquired by Bristol Myers Squibb in January 2024, where he led in vitro and in vivo biology and pharmacology functions for small molecule oncology programs, several of which reached the clinic, including adagrasib (KRAZATI), BMS-986504, MRTX1133, MRTX0902, and ORIC-944. Earlier, he was a Senior Group Leader in the Pfizer Oncology Research Unit and has more than 25 years of basic, pre-clinical, and translational research experience across academia and industry.
Frequently asked questions
- Who is Pete Olson?
- Pete Olson, PhD, is the Chief Scientific Officer at Iambic Therapeutics, a clinical-stage biotechnology company that applies AI models for protein structure prediction and drug design alongside high-throughput chemistry and biology experimentation. He previously served as VP, Research at Mirati Therapeutics, which was acquired by Bristol Myers Squibb in January 2024, where he led in vitro and in vivo biology and pharmacology functions for small molecule oncology programs, several of which reached the clinic, including adagrasib (KRAZATI), BMS-986504, MRTX1133, MRTX0902, and ORIC-944. Earlier, he was a Senior Group Leader in the Pfizer Oncology Research Unit and has more than 25 years of basic, pre-clinical, and translational research experience across academia and industry.
About this profile. Compiled from public sources — the organisations' own websites and public professional profiles — and summarised by Fundraising Fox; every fact is kept with where it came from. Spotted an error, or would rather not be listed? Email privacy@fundraisingfox.com · How we build profiles · Your rights